<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281047</url>
  </required_header>
  <id_info>
    <org_study_id>Hp.FP-10.01</org_study_id>
    <nct_id>NCT00281047</nct_id>
  </id_info>
  <brief_title>The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy</brief_title>
  <official_title>The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamamatsu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oita University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamamatsu University</source>
  <brief_summary>
    <textblock>
      FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to
      the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease
      activity (which is assumed to be produced by H. pylori) measured by the urea breath test.
      FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10
      increases the eradication rates by a triple therapy with a proton pump inhibitor,
      amoxicillin, and clarithromycin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      H. pylori -positive patients older than 15 years of age with gastritis, gastric ulcer,
      duodenal ulcer, or gastroduodenal ulcer are invited to participate in the study. These
      patients had endoscopically and histologically proven ulcers or active chronic gastritis and
      are all H. pylori-positive. Written informed consent to participation must be obtained from
      each patient before the study.

      During gastroduodenoscopy, biopsy specimens obtained from both the antrum and the corpus of
      the greater curvature are subjected to the bacterial susceptibility to clarithromycin by
      culture test or measurements of 23S rRNA mutations at positions 2142 and 2143 (from adenine
      to guanine).

      Patients are treated with 30 mg of lansoprazole bid, 200 mg of clarithromycin bid, and 750 mg
      of amoxicillin bid for one week. In addition, they take placebo bid, FP10 1 g bid, or FP-10 2
      g bid (2 hour after breakfast and at the bed time) for the same one week. Administration of
      placebo, FP-10 1 g or FP-10 2 g are performed in a double blinded manner.

      Eradication of H. pylori was confirmed by a 13C-urea breath test performed one month after
      eradication therapy. Throughout the study period, the investigators involved in the
      assessment of H. pylori eradication are blinded to susceptibility to clarithromycin H. pylori
      strains.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date>May 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of FP-01 on the eradication rates of H. pylori infection by a triple therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect o FP-10 on the eradication rates of clarithromycin-sensitive and -resistant strains of H. pylori by a triple therapy</measure>
  </secondary_outcome>
  <enrollment>138</enrollment>
  <condition>Helicobacter Pylori</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FP-10</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        H. pylori-positive patients who have never undergo the H. pylori eradication therapy -

        Exclusion Criteria:

        Patients not infected with H. pylori, Patients who are allergic to amoxicillin,
        clarithromycin, lansoprazole, 13C-urea, or milk casein
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takahisa Furuta, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Center for Clinical Research, Hamamatsu University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazunrai Murakami, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Gastroenterology, Oita University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toshio Fujioka, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oita University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takahisa Furuta, MD, PhD</last_name>
    <phone>81-53-435-2850</phone>
    <email>furuta@hama-med.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kazunari Murakami, MD, PhD</last_name>
    <phone>81-97-586-6193</phone>
    <email>murakam@med.oita-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oita Kouseiren Tsurumi Hospital</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <zip>874-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takayuki Nagai, MD. PhD</last_name>
      <phone>81-977-23-7111</phone>
      <email>ikyoku@ok-tsurumi.com</email>
    </contact>
    <investigator>
      <last_name>Takayuki Nagai, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Senoo Clinic for Internal Medicine and Gastroenterology</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3125</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazutaka Senoo, MD</last_name>
      <email>CBF00628@nifty.com</email>
    </contact>
    <investigator>
      <last_name>Kazutaka Senoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Hamamatsu University School of Medicine</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahisa Furuta, MD, PhD</last_name>
      <phone>81-53-435-2850</phone>
      <email>furuta@hama-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takahisa Furuta, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naohito Shirai, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitsushige Sugimoto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Matsushita Clinic</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>433-8121</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fumiaki Matsushita, MD, PhD</last_name>
      <phone>81-53-475-5225</phone>
      <email>fmatsushita@mail.wbs.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Fumiaki Matsushida, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kumagai Clinic for Internal Medicine and Gastroenterology</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>435-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junichi Kumagai, MD, PhD</last_name>
      <phone>81-53-422-2588</phone>
      <email>jkuma@yr.tnc.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Junichi Kumagai, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nakajima Clinic</name>
      <address>
        <city>Kakegawa</city>
        <state>Shizuoka</state>
        <zip>436</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Nakamura, MD, PhD</last_name>
      <phone>81-537-22-6819</phone>
      <email>mdnakajima@mail.wbs.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Hiroshi Nakajima, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Oita University Faculty of Medicine</name>
      <address>
        <city>Oita</city>
        <zip>879-5593</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazunari Murakami, MD, PhD</last_name>
      <phone>81-97-586-6193</phone>
      <email>murakam@med.oita-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Kazunari Murakami, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Furuta T, Sagehashi Y, Shirai N, Sugimoto M, Nakamura A, Kodaira M, Kenmotsu K, Nagano M, Egashira T, Ueda K, Yoneyama M, Ohashi K, Ishizaki T, Hishida A. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73.</citation>
    <PMID>15952098</PMID>
  </reference>
  <reference>
    <citation>Shirai N, Furuta T, Sugimoto M, Nakamura A. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy]. Nihon Rinsho. 2005 Nov;63 Suppl 11:438-41. Review. Japanese.</citation>
    <PMID>16363575</PMID>
  </reference>
  <reference>
    <citation>Okudaira K, Miura S, Furuta T, Sugimoto M, Shirai N. [Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection]. Nihon Rinsho. 2005 Nov;63 Suppl 11:391-6. Review. Japanese.</citation>
    <PMID>16363566</PMID>
  </reference>
  <reference>
    <citation>Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005 Jun;20(3):153-67. Review.</citation>
    <PMID>15988117</PMID>
  </reference>
  <reference>
    <citation>Furuta T, Shirai N, Sugimoto M, Nakamura A, Okudaira K, Kajimura M, Hishida A. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Aliment Pharmacol Ther. 2005 Jul 1;22(1):67-74.</citation>
    <PMID>15963082</PMID>
  </reference>
  <reference>
    <citation>Okudaira K, Furuta T, Shirai N, Sugimoto M, Miura S. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. Aliment Pharmacol Ther. 2005 Feb 15;21(4):491-7. Erratum in: Aliment Pharmacol Ther. 2005 Jun 1;21(11):1398.</citation>
    <PMID>15710002</PMID>
  </reference>
  <reference>
    <citation>Murakami K, Fujioka T. [Drug resistant H. pylori in Japan: general remarks]. Nihon Rinsho. 2005 Nov;63 Suppl 11:198-202. Review. Japanese.</citation>
    <PMID>16363531</PMID>
  </reference>
  <reference>
    <citation>Murakami K, Kodama M, Sato R, Okimoto T, Watanabe K, Fujioka T. Helicobacter pylori eradication and associated changes in the gastric mucosa. Expert Rev Anti Infect Ther. 2005 Oct;3(5):757-64. Review.</citation>
    <PMID>16207167</PMID>
  </reference>
  <reference>
    <citation>Murakami K, Sato R, Okimoto T, Watanabe K, Nasu M, Fujioka T, Kodama M, Kagawa J. Influence of anti-ulcer drugs used in Japan on the result of (13)C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol. 2003;38(10):937-41.</citation>
    <PMID>14614600</PMID>
  </reference>
  <reference>
    <citation>Hiramoto S, Itoh K, Shizuuchi S, Kawachi Y, Morishita Y, Nagase M, Suzuki Y, Nobuta Y, Sudou Y, Nakamura O, Kagaya I, Goshima H, Kodama Y, Icatro FC, Koizumi W, Saigenji K, Miura S, Sugiyama T, Kimura N. Melanoidin, a food protein-derived advanced maillard reaction product, suppresses Helicobacter pylori in vitro and in vivo. Helicobacter. 2004 Oct;9(5):429-35.</citation>
    <PMID>15361082</PMID>
  </reference>
  <reference>
    <citation>Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther. 2003 Jan;17(1):119-23.</citation>
    <PMID>12492740</PMID>
  </reference>
  <reference>
    <citation>Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J, Sato S, Abe H, Arita T. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2002 Nov;16(11):1933-8.</citation>
    <PMID>12390102</PMID>
  </reference>
  <reference>
    <citation>Murakami K, Nasu M. [Clarithromycin (CAM)]. Nihon Rinsho. 2002 Feb;60 Suppl 2:667-70. Review. Japanese.</citation>
    <PMID>11979867</PMID>
  </reference>
  <reference>
    <citation>Murakami K, Nasu M. [Drug sensitivity test for Helicobacter pylori]. Nihon Rinsho. 2002 Feb;60 Suppl 2:350-3. Review. Japanese.</citation>
    <PMID>11979806</PMID>
  </reference>
  <reference>
    <citation>Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents. 2002 Jan;19(1):67-70.</citation>
    <PMID>11814770</PMID>
  </reference>
  <reference>
    <citation>Asaka M, Satoh K, Sugano K, Sugiyama T, Takahashi S, Fukuda Y, Ota H, Murakami K, Kimura K, Shimoyama T. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter. 2001 Sep;6(3):177-86.</citation>
    <PMID>11683920</PMID>
  </reference>
  <reference>
    <citation>Murakami K, Fujioka T, Kodama R, Kubota T, Tokieda M, Nasu M. Helicobacter pylori infection accelerates human gastric mucosal cell proliferation. J Gastroenterol. 1997 Apr;32(2):184-8.</citation>
    <PMID>9085165</PMID>
  </reference>
  <verification_date>January 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2006</study_first_posted>
  <last_update_submitted>January 26, 2006</last_update_submitted>
  <last_update_submitted_qc>January 26, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2006</last_update_posted>
  <keyword>Helicobacter pylori (H. pylori)</keyword>
  <keyword>FP-10</keyword>
  <keyword>amoxicillin</keyword>
  <keyword>clarithromycin</keyword>
  <keyword>lansoprazole</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

